Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc Analyst R&D Day Transcript

Oct 18, 2019 / 12:30PM GMT
Release Date Price: €33.15 (+7.49%)
Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Everybody, thanks so much for joining us today. We are here for Arrowhead's Analyst Day in 2019.

And here is our forward-looking statement slide, it just says we will be making forward-looking statements today and please refer to all the disclosures and risk factors in our filings.

So today, what are we going to cover and who is going to talk to you? It's always nice to do these kind of events because we do a lot of broker conferences and scientific and medical meetings and we do our conference calls, but they're kind of quick hits. So we're only able to talk about certain targeted things and we're never really able to take a step back and talk about where were we, how far have we come and where are we going in the future and what's our strategy and what makes our R&D organization tick, and so that's what we're going to try to hit today.

So from the company, myself, and most of you know me, I'm Vince Anzalone, the Head of Investor Relations; Chris Anzalone, our President and CEO; Bruce Given, our COO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot